Literature DB >> 6980698

High-dose methotrexate with citrovorum factor and vincristine in the treatment of malignant mesothelioma.

N V Dimitrov, J Egner, E Balcueva, L G Suhrland.   

Abstract

The incidence of malignant mesothelioma has increased greatly in the last 40 years. Current and recent past exposure to asbestos is expected to substantially increase this incidence. We report nine cases of malignant mesothelioma which temporarily responded to treatment with high-dose methotrexate-citrovorum rescue and vincristine. Further clinical trials of high-dose methotrexate with citrovorum rescue appear indicated in this disease.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6980698     DOI: 10.1002/1097-0142(19821001)50:7<1245::aid-cncr2820500704>3.0.co;2-h

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

Review 1.  Chemotherapy in malignant mesothelioma: a review.

Authors:  A Krarup-Hansen; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

2.  Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients.

Authors:  M R Law; A Gregor; M E Hodson; H J Bloom; M Turner-Warwick
Journal:  Thorax       Date:  1984-04       Impact factor: 9.139

Review 3.  Current therapy for malignant mesothelioma.

Authors:  W Roy Smythe
Journal:  Curr Oncol Rep       Date:  2002-07       Impact factor: 5.945

4.  High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study.

Authors:  O P Solheim; G Saeter; A M Finnanger; A E Stenwig
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

Review 5.  Chemotherapy for malignant pleural mesothelioma: past results and recent developments.

Authors:  S Tomek; S Emri; K Krejcy; C Manegold
Journal:  Br J Cancer       Date:  2003-01-27       Impact factor: 7.640

6.  High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma.

Authors:  M Halme; A Knuuttila; T Vehmas; L Tammilehto; M Mäntylä; J Salo; K Mattson
Journal:  Br J Cancer       Date:  1999-08       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.